Primary sclerosing cholangitis: review of recommendations for diagnosis and treatment of disease

Cover Page

Cite item

Full Text

Abstract

Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease with unknown etiology. In recent years, there is steady increase in the incidence of PSC. However, this disease is poorly known to practitioners still. Within last 10 years, leading hepatological associations have developed or updated the current recommendations on PSC. That allowed to standardize approaches to diagnosis and treatment of the disease. However, there are still more questions than answers in the understanding of PSC, and it remains a scientific and clinical problem. Primary diagnosis and treatment of the disease are the sharpest issues. The purpose of this review was to summarize current and advanced concepts in the diagnosis and treatment of the disease. We analyzed recommendations of the leading gastroenterological (hepatological) associations on PSC. As a result, we have received the most complete comprehension on the features of diagnosis and treatment modalities for PSC at the present stage of the development of medicine. Currently, none of the medicinal products are proved to be effective on patient's survival rate, and liver transplantation remains the only treatment that improves prognosis of the patients with PSC. At the same time, there are many observations on effectiveness of ursodeoxycholic acid in PSC, which explains its wide use in this group of patients. We also presented our own experience in diagnosing and treating of a patient with PSC.

About the authors

K. L Raikhelson

Saint Petersburg State University

Email: kraikhelson@mail.ru
д-р мед. наук, проф. Научно-клинического и образовательного центра гастроэнтерологии и гепатологии ФГБОУ ВО СПбГУ 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9

E. V Pazenko

Saint Petersburg State University

Email: kaboi@rambler.ru
мл. науч. сотр. Научно-клинического и образовательного центра гастроэнтерологии и гепатологии ФГБОУ ВО СПбГУ 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9

N. V Marchenko

Saint Petersburg State University

Email: dr.marchenko@gmail.com
канд. мед. наук, доц. Научно-клинического и образовательного центра гастроэнтерологии и гепатологии ФГБОУ ВО СПбГУ 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9

References

  1. Navaneethan U, Parasa S, Venkatesh P.G. Impact of inflammatory bowel disease on post - cholecystectomy complications and hospitalization costs: a Nationwide Inpatient Sample study. J Crohns Colitis 2013; 7 (5): 164-70.
  2. Ngu J.H, Gearry R.B, Wright A.J et al. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9 (12): 1092-7.
  3. Boonstra K, Beuers U, Ponsioen C.Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56 (5): 1181-8.
  4. Keith D, Lindor M.D, Kris V et al. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Gastroenterology 2015; 110 (5): 646-59.
  5. European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol 2017; 66 (6): 1265-81.
  6. Lunder A.K, Hov J.R, Borthne A et al. Prevalence of sclerosing cholangitis, detected by magnetic resonance cholangiography, in patients with longterm inflammatory bowel disease. Gastroenterology 2016; 151: 660-9, e4.
  7. Ивашкин В.Т., Широкова В.Т., Маевская М.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 2: 41-57.
  8. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol 2009; 51 (2): 237-67.
  9. Ang T.L, Tischendorf J, Hecker H et al. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002; 17 (8): 908-13.
  10. Schrumpf E, Abdelnoor M, Fausa O et al. Risk factors in primary sclerosing cholangitis. J Hepatol 1994; 21: 1061-6.
  11. Chapman R, Fevery J, Kallo A et al. Diagnosis and management of primary sclerosing cholangitis. J Hepatol 2010; 51 (2): 660-8.
  12. Boberg K.M, Chapman R.W, Hirschfield G.M et al. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue on behalf of the International Autoimmune Hepatitis Group. J Hepatol 2011; 54 (2): 374-85.
  13. Hirschfield G.M, Karlsen T.H, Lindor K.D et al. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-99.
  14. Karlsen T.H, Franke A, Melum E et al. Genome - wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-11.
  15. Melum E, Franke A, Schramm C et al. Genome - wide association analysis in primary sclerosing cholangitis identifies two non - HLA susceptibility loci. Nat Genet. 2011; 43: 17-9.
  16. Harbord M, Annese V, Vavricka S.R et al. The First European Evidence - based Consensus on Extra - intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10 (3): 239-54.
  17. Meagher S, Yusoff I, Kennedy W et al. The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost - effectiveness analysis. Endoscopy 2007; 39: 222-8.
  18. Райхельсон К.Л., Карев В.Е., Марченко Н.В. и др. Морфологическая дифференциальная диагностика аутоиммунных заболеваний печени в клинической практике. Профилакт. и клин. медицина. 2013; 2 (47): 43-9.
  19. Van Hoogstraten H.J, Wolfhagen F.H, van de Meeberg P.C et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998; 29 (3): 417-23.
  20. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis - Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-5.
  21. Olsson R, Boberg K.M, de Muckadell O.S et al. High - dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-72.
  22. Mitchell S.A, Bansi D.S, Hunt N et al. A preliminary trial of high - dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-7.
  23. Poropat G, Giljaca V, Stimac D et al. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2011; 19 (1): CD003626. doi: 10.1002/14651858. CD003626.pub2.
  24. Hansen J.D, Kumar S, Lo W.K et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta - analysis. Dig Dis Sci 2013; 58 (11): 3079-87.
  25. Cullen S.N, Rust C, Fleming K et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48 (5): 792-800.
  26. Lindor K.D, Enders F.B, Schmoll J.A et al. Randomized, double - blind controlled trial of high dose ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 2008; 48: 378A.
  27. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016; 62 (4): 60-84.
  28. Dickson E.R, Murtaugh P.A, Wiesner R.H et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology. 1992; 103 (6): 1893-901.
  29. Farrant J.M. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100 (6): 1710-7.
  30. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Redesigning liver distribution to reduce variation in access to liver transplantation. [February 8, 2016].
  31. Райхельсон К.Л., Прашнова М.К. Урсодезоксихолевая кислота: существующие рекомендации и перспективы применения. Доктор.ру. 2015; 12 (113): 50-6.
  32. Плотникова Е.Ю., Сухих А.С. Урсодезоксихолевая кислота вчера и сегодня. Терапевт. 2012; 7: 23-32.
  33. Багишева Н.В., Трухан Д.И., Гришечкина И.А. и др. Эффективность урсодезоксихолевой кислоты при билиарном сладже у женщин. Современные наукоемкие технологии. 2014; 12 (1): 98-9.
  34. Эсауленко Е.В., Никитина О.Е., Дунаева Н.В. и др. Опыт применения урсодеоксихолевой кислоты («Урдокса») в комплексной терапии хронического вирусного гепатита. Журн. инфектологии. 2011; 3 (3): 42-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).